全文获取类型
收费全文 | 22109篇 |
免费 | 1695篇 |
国内免费 | 613篇 |
专业分类
耳鼻咽喉 | 105篇 |
儿科学 | 289篇 |
妇产科学 | 188篇 |
基础医学 | 1489篇 |
口腔科学 | 175篇 |
临床医学 | 1915篇 |
内科学 | 5119篇 |
皮肤病学 | 308篇 |
神经病学 | 1124篇 |
特种医学 | 298篇 |
外国民族医学 | 1篇 |
外科学 | 2448篇 |
综合类 | 1634篇 |
现状与发展 | 2篇 |
预防医学 | 662篇 |
眼科学 | 228篇 |
药学 | 5371篇 |
11篇 | |
中国医学 | 312篇 |
肿瘤学 | 2738篇 |
出版年
2024年 | 35篇 |
2023年 | 488篇 |
2022年 | 727篇 |
2021年 | 1061篇 |
2020年 | 1000篇 |
2019年 | 893篇 |
2018年 | 829篇 |
2017年 | 895篇 |
2016年 | 817篇 |
2015年 | 915篇 |
2014年 | 1243篇 |
2013年 | 2471篇 |
2012年 | 1155篇 |
2011年 | 1349篇 |
2010年 | 1011篇 |
2009年 | 1024篇 |
2008年 | 983篇 |
2007年 | 933篇 |
2006年 | 874篇 |
2005年 | 681篇 |
2004年 | 558篇 |
2003年 | 545篇 |
2002年 | 495篇 |
2001年 | 388篇 |
2000年 | 326篇 |
1999年 | 273篇 |
1998年 | 267篇 |
1997年 | 256篇 |
1996年 | 199篇 |
1995年 | 187篇 |
1994年 | 150篇 |
1993年 | 152篇 |
1992年 | 118篇 |
1991年 | 105篇 |
1990年 | 96篇 |
1989年 | 92篇 |
1988年 | 76篇 |
1987年 | 93篇 |
1986年 | 59篇 |
1985年 | 86篇 |
1984年 | 77篇 |
1983年 | 52篇 |
1982年 | 78篇 |
1981年 | 53篇 |
1980年 | 55篇 |
1979年 | 46篇 |
1978年 | 45篇 |
1977年 | 28篇 |
1976年 | 27篇 |
1973年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
目的探讨降低呼吸机相关性肺炎(VAP)发生率的方法。方法选取符合人选标准的接受气管插管机械通气的患者为研究对象,将患者随机分为研究组和对照组,两组患者的常规治疗方法相同,研究组应用硫糖铝混悬液2g,3次/d鼻饲;对照组应用泮托拉唑40mg,2次/d静脉滴注。记录急性上消化道出血(AUGIB)和VAP的发生情况。结果两组患者轻中度AUGIB(黑便和咖啡色胃液)的发生率比较,差异无统计学意义(P〉O.05):对照组VAP的发生率明显高于研究组(P〈0.05)。结论对于有轻中度应激性溃疡风险的患者,应用硫糖铝在较好预防AUBIG发生的同时可明显降低发生VAP的风险。 相似文献
992.
Kaelo K. Seatla Dorcas Maruapula Wonderful T. Choga Tshenolo Ntsipe Nametso Mathiba Mompati Mogwele Max Kapanda Bornapate Nkomo Dinah Ramaabya Joseph Makhema Mompati Mmalane Madisa Mine Ishmael Kasvosve Shahin Lockman Sikhulile Moyo Simani Gaseitsiwe 《Viruses》2021,13(4)
There are limited real-world mutational and virological outcomes data of treatment-experienced persons diagnosed with HIV-1 subtype C (HIV-1 C) who are failing Integrase Strand Transfer Inhibitor-based regimens. Requisition forms sent for HIV-1 genotypic resistance testing (GRT) between May 2015 and September 2019 were reviewed and participants experiencing virologic failure while on dolutegravir (DTG) or raltegravir (RAL) cART at sampling recruited. Sanger sequencing of the HIV-1 Pol gene was performed from residual plasma samples and drug resistance mutational (DRM) analysis performed using the Stanford University HIV drug resistance database. 40 HIV-1C integrase sequences were generated from 34 individuals, 24 of whom were on DTG cART, three on RAL cART and seven on an unknown (DTG or RAL)-anchored cART at time of GRT. 11/34 (32%) individuals had DRMs to DTG and other integrase inhibitors. 7/11 (64%) patients had exposure to a RAL-based cART at the time of sampling. Out of the 11 individuals with DRMs, one (9%) had 2-class, 6 (55%) had 3-class, and 4 (36%) had 4-class multidrug-resistant HIV-1C. 7/11 individuals (64%) are currently virologically suppressed. Of the four individuals not virologically suppressed, three had extensive DRMs involving 4-classes of ARV drugs and one individual has demised. Resistance to DTG occurs more often in patients exposed to RAL cART. Individuals with 4-class DRMs plus integrase T97 and E157Q mutations appear to have worse outcomes. There is a need for frequent VL monitoring and GRT amongst treatment-experienced HIV-1C diagnosed individuals. 相似文献
993.
Laura Albentosa-Gonzlez Nereida Jimenez de Oya Armando Arias Pilar Clemente-Casares Miguel ngel Martin-Acebes Juan Carlos Saiz Rosario Sabariegos Antonio Mas 《Viruses》2021,13(5)
Arthropod-borne flaviviruses, such as Zika virus (ZIKV), Usutu virus (USUV), and West Nile virus (WNV), are a growing cause of human illness and death around the world. Presently, no licensed antivirals to control them are available and, therefore, search for broad-spectrum antivirals, including host-directed compounds, is essential. The PI3K/Akt pathway controls essential cellular functions involved in cell metabolism and proliferation. Moreover, Akt has been found to participate in modulating replication in different viruses including the flaviviruses. In this work we studied the interaction of flavivirus NS5 polymerases with the cellular kinase Akt. In vitro NS5 phosphorylation experiments with Akt showed that flavivirus NS5 polymerases are phosphorylated and co-immunoprecipitate by Akt. Polymerase activity assays of Ala- and Glu-generated mutants for the Akt-phosphorylated residues also indicate that Glu mutants of ZIKV and USUV NS5s present a reduced primer-extension activity that was not observed in WNV mutants. Furthermore, treatment with Akt inhibitors (MK-2206, honokiol and ipatasertib) reduced USUV and ZIKV titers in cell culture but, except for honokiol, not WNV. All these findings suggest an important role for Akt in flavivirus replication although with specific differences among viruses and encourage further investigations to examine the PI3K/Akt/mTOR pathway as an antiviral potential target. 相似文献
994.
995.
Amra Simic MA Pernelle K. Schøndorff MSc Tobias Stumpe BSc Matthias Heschel PhD Werner Regittnig PhD Tina Pöttler Daniela Ninaus MSc Thomas Augustin PhD Andrea Groselj-Strele PhD Thomas R. Pieber MD Julia K. Mader MD 《Diabetes, obesity & metabolism》2021,23(6):1402-1408
Maintaining good glycaemic control with the same infusion set for longer than 3 days may improve the quality of life of insulin pump users. The aim of the current study was to assess the efficacy and safety of the novel, extended-wear infusion set over 7 days of wear in adults with type 1 diabetes. Sixteen participants completed three identical 8-hour euglycaemic clamp experiments on Days 1, 4 and 7 of infusion set wear. Between the experiments, the participants were discharged home for routine diabetes management while wearing the same extended-wear infusion set throughout the study. Time to reach the maximum glucose infusion rate (TGIRmax) on Day 7 was reduced by 67% compared with Day 1 (p < .001). The corresponding area under the glucose infusion rate curve (AUCGIR) was comparable for the first 2 h of the clamp (p = .891) but decreased by 28% over time (p < .008). While the extent of insulin absorption decreased with prolonged wear, it was accompanied by an increase in insulin absorption rate. The infusion set survival rate was 100% without leakages, occlusion alarms, severe hypoglycaemia or ketoacidosis. The extended-wear infusion set proved safe and effective during prolonged wear in real-life conditions. 相似文献
996.
Rune E. Kuhre PhD Carolyn F. Deacon DMSci Nicolai J. Wewer Albrechtsen PhD Jens J. Holst DMSci 《Diabetes, obesity & metabolism》2021,23(9):2009-2019
Sodium-glucose co-transporter-2 inhibitors (SGLT2is) lower blood glucose and are used for treatment of type 2 diabetes. However, SGLT2is have been associated with increases in endogenous glucose production (EGP) by mechanisms that have been proposed to result from SGLT2i-mediated increases in circulating glucagon concentrations, but the relative importance of this effect is debated, and mechanisms possibly coupling SGLT2is to increased plasma glucagon are unclear. A direct effect on alpha-cell activity has been proposed, but data on alpha-cell SGLT2 expression are inconsistent, and studies investigating the direct effects of SGLT2 inhibition on glucagon secretion are conflicting. By contrast, alpha-cell sodium-glucose co-transporter-1 (SGLT1) expression has been found more consistently and appears to be more prominent, pointing to an underappreciated role for this transporter. Nevertheless, the selectivity of most SGLT2is does not support interference with SGLT1 during therapy. Paracrine effects mediated by secretion of glucagonotropic/static molecules from beta and/or delta cells have also been suggested to be involved in SGLT2i-induced increase in plasma glucagon, but studies are few and arrive at different conclusions. It is also possible that the effect on glucagon is secondary to drug-induced increases in urinary glucose excretion and lowering of blood glucose, as shown in experiments with glucose clamping where SGLT2i-associated increases in plasma glucagon are prevented. However, regardless of the mechanisms involved, the current balance of evidence does not support that SGLT2 plays a crucial role for alpha-cell physiology or that SGLT2i-induced glucagon secretion is important for the associated increased EGP, particularly because the increase in EGP occurs before any rise in plasma glucagon. 相似文献
997.
998.
999.
Rayhan A. Lal MD Liana Hsu BS Jian Zhang MD Pernelle K. Schøndorff MS Matthias Heschel PhD Bruce Buckingham MD 《Diabetes, obesity & metabolism》2021,23(8):1973-1977
Current insulin infusion sets are approved for only 2-3 days. The novel ConvaTec infusion set with Lantern technology is designed to extend infusion set wear time. The goal of this pilot study was to evaluate the duration of wear for this set. This was a pilot safety study in adults with type 1 diabetes using tethered insulin pumps. Participants inserted the set and wore it for 10 days or until failure. Among 24 participants, two were excluded. Forty-five per cent of the sets lasted 10 days. Median wear time was 9.1 (7.1, 10.0) days. Among 12 premature failures, six (50%) involved adhesive failures, four (33%) hyperglycaemia unresponsive to correction, one (8%) hyperglycaemia with ketones and one (8%) infection. Average CGM glucose per day of infusion set wear showed a statistically significant increase over time, while total daily insulin over the same period did not change. In this pilot study, the duration of wear for the novel infusion set exceeded previously reported commercial sets (P < .001). This extended wear technology may eventually allow for a combined glucose sensor and infusion set. 相似文献
1000.
JL Adams M Murray N Patel MT Sawkin RC Boardman C Pham H Kaur D Patel JL Yager L Pontiggia J Baxter 《HIV medicine》2021,22(1):28-36